EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of PSMD11 as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression

Qiumin Huang, Ran Tian, Jinxi Yu, Wei Du iD

Cancer Medicine · 2024-06 · 13 (11)

DOI: 10.1002/cam4.7379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.06.2024. Verfasst von Qiumin Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Biochemistry and Molecular Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Key La…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Health Research Project, Tianjin Key Medical Discipline (Specialty) Construction Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to the unfavorable prognosis associated with lung adenocarcinoma (LUAD), the development of targeted therapies and immunotherapies is essential. Cuproptosis, an emerging form of regulated cell death, is implicated in mitochondrial metabolism and is induced by copper ions. This study aimed to explore the prognostic value of cuproptosis‐ and immune‐related genes (CIRGs) in LUAD.

Methods

We used The Cancer Genome Atlas database to develop a prognostic prediction model for LUAD patients based on eight CIRGs. Using Cox regression analysis, we determined that the CIRG signature is a reliable, independent prognostic factor. We further identified PSMD11 as a critical CIRG and performed immunohistochemistry to study the protein expression levels of PSMD11 in LUAD tissues. We also investigated the impact of PSMD11 on the biological behavior of lung cancer cell lines.

Results

We found that patients with low PSMD11 expression levels displayed an improved prognosis compared with those with high PSMD11 expression levels. Overexpression of PSMD11 enhanced proliferation, migration, invasion, and tumor growth of lung carcinoma cell line A549, while PSMD11 knockdown diminished proliferation, migration, invasion, and tumor growth of lung carcinoma cell line PC9. Additionally, we discovered that PSMD11 expression was positively correlated with the infiltration of myeloid‐derived suppressor cells and the increased expression of immunosuppressive molecules.

Conclusion

These findings suggest that PSMD11 may serve as a valuable prognostic biomarker and therapeutic target for LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsAnimalsFemaleHumansMaleMiceA549 CellsCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticPrognosis

Stichwörter der Autor:innen

PSMD11cuproptosisimmune cellslung adenocarcinomaprognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Immunology, Biochemistry and Molecular Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Key Laboratory of Medical Epigenetics, Key Laboratory of Immune Microenviron…
  • Department of Laboratory and Diagnosis, Changhai Hospital, Navy Medical University, Shanghai, China.
  • Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, China.
  • Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.

ORCID-Profile: Wei Du

Förderung

  • Tianjin Health Research Project
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • National Natural Science Foundation of China

Zitieren

APA

Huang, Q., Tian, R., Yu, J., & Du, W. (2024). Identification of PSMD11 as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression. Cancer Medicine, 13(11). https://doi.org/10.1002/cam4.7379

Vancouver

Huang Q, Tian R, Yu J, Du W. Identification of PSMD11 as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression. Cancer Medicine. 2024;13(11). doi:10.1002/cam4.7379

BibTeX
@article{Huang2024,
  author = {Huang, Qiumin and Tian, Ran and Yu, Jinxi and Du, Wei},
  title = {Identification of PSMD11 as a novel cuproptosis‐ and immune‐related prognostic biomarker promoting lung adenocarcinoma progression},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {11},
  doi = {10.1002/cam4.7379}
}
Kostenlos starten →